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increases in both plasma volu 
and renin system activity that 
inhibitor captopril with minoxidil as the third drug choice in 
triple therapy of resistant hypertension and define the subtle 
differences in these two potent antihypertensive agents. The 
patients in their were 
hypertension if th stolic 
eart rate m t 
s (6) correctly point gut that t 
rone was actually higher in the group treated with the 
angiote~si~-~onverti yme ~ah~bitor than in the group 
treated with minoxi is well appreciated that urinary 
aldosterone may be a better reflection of sodium intake and 
angiotensin-converting enzyme inhibition during long-term 
therapy; nonetheless. the absence of at least qualitative 
aldosterone suppression is somewhat surprising. 
The authors (6) are candid -ith respect to the effect of 
captopril on left ventricular mass. Although there was a 
of left ventricular mass in the overall 
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ass is more likely to decrease in resistant hy 
aptspril-based therapy, this response is not necessar- 
ily uniform. An additio.lal caveat to this s 
captopril was administered in co 
metoprolol. Thus, whether the 
captopril alone or to the combined influence of this triple 
drug therapy cannot be differentiated in this study. 
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EDITORIALCOMMENT 
Therapeutic implications. As stated in a now classic 
clinical review (I), “truly resistant” hypertension is not that 
common in the era of effective pharmacologic therapy. 
Although practicing clinicians welcome reports of “effective 
monotherapy” of hypertension i the hope of achieving 
favorable blood pressure control at minimal cost and mor- 
bidity, the reality of clinical practice is that ,nany patients 
continue to require several agents for blood pressure con- 
trol. The current study by Julien et al. (6) adds further 
convincing evidence to the concept hat blood pressure 
reduction alone may not be a sufficient end point of antihy 
pertensive therapy. A combination f therapies that amelio- 
rates target organ abnormalities may be preferable, particu- 
larly by blocking adverse contributions of neurohormonal 
pathways. The evidence for the adverse influence of the 
sympathetic nervous ystem and renin-angiotensin system 
on left ventricular hypertrophy continues toincrease (B-10). 
Unfortunately, these abnormalities are often best addressed 
in experimental studies that do no: closely mimic human 
resistant hypertension. Nonetheless, the observations and 
implications from drug interventions specifically targeted 
toward neurohormonal p thways i very convincing. 
“Resistant hypertension,” defined as the requirement of 
two or more antihypertensive drugs for blood pressure 
control, will continue to include a significant proportion of 
the hypertensive population. Therefore, well defined and 
executed studies uch as that by Julien and coworkers (6) 
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will help delineate pragmatic and clinically relevant a 
proaches to effective and antihypertensive th
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